Mirabella Financial Services LLP Takes $1.16 Million Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

Mirabella Financial Services LLP acquired a new stake in Roivant Sciences Ltd. (NASDAQ:ROIV) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 157,072 shares of the company’s stock, valued at approximately $1,159,000.

Other institutional investors also recently modified their holdings of the company. Citigroup Inc. raised its holdings in shares of Roivant Sciences by 1,803.6% in the 1st quarter. Citigroup Inc. now owns 5,749 shares of the company’s stock valued at $28,000 after purchasing an additional 5,447 shares during the period. Royal Bank of Canada boosted its stake in shares of Roivant Sciences by 60,550.0% during the 1st quarter. Royal Bank of Canada now owns 6,065 shares of the company’s stock worth $30,000 after acquiring an additional 6,055 shares during the period. Jane Street Group LLC bought a new position in shares of Roivant Sciences during the 3rd quarter worth approximately $48,000. BNP Paribas Arbitrage SNC bought a new position in shares of Roivant Sciences during the 3rd quarter worth approximately $49,000. Finally, Hsbc Holdings PLC boosted its stake in shares of Roivant Sciences by 25.4% during the 1st quarter. Hsbc Holdings PLC now owns 14,684 shares of the company’s stock worth $71,000 after acquiring an additional 2,978 shares during the period. 64.76% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have recently commented on ROIV. JPMorgan Chase & Co. lifted their target price on Roivant Sciences from $14.00 to $16.00 in a research note on Friday, July 14th. Truist Financial reissued a “buy” rating and issued a $23.00 price objective on shares of Roivant Sciences in a research report on Friday, July 14th. HC Wainwright reissued a “buy” rating and issued a $18.00 price objective on shares of Roivant Sciences in a research report on Tuesday, August 15th. Bank of America boosted their price objective on Roivant Sciences from $10.50 to $11.00 in a report on Friday, June 23rd. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $15.00 price objective on shares of Roivant Sciences in a report on Thursday. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $14.75.

Roivant Sciences Trading Up 1.0 %

Roivant Sciences stock traded up $0.11 during mid-day trading on Monday, reaching $11.68. 3,710,500 shares of the company were exchanged, compared to its average volume of 3,671,606. The company has a fifty day simple moving average of $11.06 and a 200-day simple moving average of $9.44. Roivant Sciences Ltd. has a 12 month low of $2.87 and a 12 month high of $12.01. The company has a debt-to-equity ratio of 0.29, a current ratio of 6.37 and a quick ratio of 6.37.

Roivant Sciences (NASDAQ:ROIV) last posted its quarterly earnings data on Monday, August 14th. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.10). Roivant Sciences had a negative return on equity of 73.68% and a negative net margin of 1,233.11%. The company had revenue of $21.60 million for the quarter, compared to the consensus estimate of $24.49 million. During the same quarter last year, the business earned ($0.48) EPS. Roivant Sciences’s revenue was up 402.3% on a year-over-year basis. As a group, equities analysts anticipate that Roivant Sciences Ltd. will post -1.06 EPS for the current year.

Insider Buying and Selling

In related news, major shareholder Global Investors Lp Viking sold 13,000,000 shares of Roivant Sciences stock in a transaction that occurred on Thursday, June 22nd. The shares were sold at an average price of $9.90, for a total value of $128,700,000.00. Following the transaction, the insider now directly owns 641,010 shares of the company’s stock, valued at $6,345,999. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, major shareholder Global Investors Lp Viking sold 13,000,000 shares of the company’s stock in a transaction on Thursday, June 22nd. The stock was sold at an average price of $9.90, for a total transaction of $128,700,000.00. Following the completion of the sale, the insider now directly owns 641,010 shares in the company, valued at approximately $6,345,999. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CAO Rakhi Kumar sold 43,893 shares of the company’s stock in a transaction on Friday, June 9th. The stock was sold at an average price of $9.93, for a total value of $435,857.49. Following the sale, the chief accounting officer now owns 198,582 shares of the company’s stock, valued at $1,971,919.26. The disclosure for this sale can be found here. Insiders sold 13,830,357 shares of company stock valued at $137,653,918 over the last quarter. 4.60% of the stock is owned by company insiders.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.